| Drug Type Chemical drugs | 
| Synonyms | 
| Target | 
| Action inhibitors, antagonists | 
| Mechanism NTRK inhibitors(Neurotrophic tyrosine kinase receptor inhibitors), VEGFR antagonists(Vascular endothelial growth factor receptor antagonists), c-Met inhibitors(Hepatocyte growth factor receptor inhibitors) | 
| Therapeutic Areas | 
| Active Indication | 
| Inactive Indication- | 
| Inactive Organization- | 
| License Organization- | 
| Drug Highest PhaseIND Approval | 
| First Approval Date- | 
| Regulation- | 
| Indication | Highest Phase | Country/Location | Organization | Date | 
|---|---|---|---|---|
| Gastrointestinal Neoplasms | IND Approval | United States  | 29 Dec 2023 | |
| Neoplasms | Preclinical | China  | 02 Feb 2021 | 





